Ranibizumab

"Ranibizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.

Descriptor ID	D000069579
MeSH Number(s)	D12.776.124.486.485.114.224.060.868 D12.776.124.790.651.114.224.060.868 D12.776.377.715.548.114.224.200.868
Concept/Terms	Ranibizumab Ranibizumab RhuFab V2 V2, RhuFab Lucentis Lucentis

Below are MeSH descriptors whose meaning is more general than "Ranibizumab".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Ranibizumab [D12.776.377.715.548.114.224.200.868]

Below are MeSH descriptors whose meaning is related to "Ranibizumab".

Below are MeSH descriptors whose meaning is more specific than "Ranibizumab".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ranibizumab" by people in this website by year, and whether "Ranibizumab" was a major or minor topic of these publications.

Bar chart showing 120 publications over 19 distinct years, with a maximum of 16 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	0	4	4
2008	0	5	5
2009	0	4	4
2010	0	5	5
2011	0	4	4
2012	0	3	3
2013	0	3	3
2014	1	6	7
2015	2	5	7
2016	1	4	5
2017	1	0	1
2018	4	4	8
2019	6	6	12
2020	5	5	10
2021	4	8	12
2022	2	5	7
2023	2	4	6
2024	8	8	16
2025	1	0	1

Below are the most recent publications written about "Ranibizumab" by people in Profiles.

Magrath G, Luvisi J, Russakoff D, Oakley J, Say EA, Blice J, Jayagopal A, Tucker S, Loayza A, Baker GH, Obeid JS. Use of a Convolutional Neural Network to Predict the Response of Diabetic Macular Edema to Intravitreal Anti-VEGF Treatment: A Pilot Study. Am J Ophthalmol. 2025 May; 273:176-181.

View in: PubMed
Swaminathan S, Mahmoudzadeh R, Wakabayashi T, Bowers M, Momenaei B, Abishek RM, Salabati M, Hsu J, Dunn JP. OUTCOMES OF PRO RE NATA VERSUS TREAT-AND-EXTEND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR MYOPIC MACULAR NEOVASCULARIZATION IN MULTIETHNIC PATIENTS IN THE UNITED STATES. Retina. 2024 12 01; 44(12):2057-2065.

View in: PubMed
Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, Gupta V, Dunn JP, Lightman SL, Thorne JE, Kim RY, Yeh S, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2025 May; 132(5):527-537.

View in: PubMed
Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR. Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration. Am J Ophthalmol. 2025 Feb; 270:172-182.

View in: PubMed
Alsoudi AF, Wai KM, Koo E, Parikh R, Mruthyunjaya P, Rahimy E. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2024 10 01; 142(10):972-975.

View in: PubMed
Durrani AF, Momenaei B, Wakabayashi T, Vemula S, Pandit SA, Hsu J, Ho AC, Spirn MJ, Klufas MA, Garg SJ, Vander JF, Regillo CD, Chiang A, Kuriyan AE, Yonekawa Y. Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema. Br J Ophthalmol. 2024 08 22; 108(9):1257-1262.

View in: PubMed
Lin TY, Hsieh YT, Garg SJ, Chen LJ, Chen KJ, Wu WC, Lai CC, Hwang YS, Kang EY. Systemic effects of anti-VEGF intravitreal injection in patients with age-related macular degeneration: A multi-institutional real-world study. Indian J Ophthalmol. 2024 11 01; 72(Suppl 5):S809-S815.

View in: PubMed
Dang S, Parke DW, Sodhi GS, Eichenbaum D, Nielsen J, Danzig C, Lalwani G, Moinfar N, London N, Kimura A, Jumper JM, Lord K, Sheth V, Pieramici D, Orlin A, Madson A, Horton M, Blim J, Cao JA, Thompson J, Khanna S, Wykoff CC, Shah AR. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 08 01; 142(8):716-721.

View in: PubMed
Shah S, Chou B, Patel M, Watane A, Shah L, Yannuzzi N, Sridhar J. Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S. Curr Opin Ophthalmol. 2024 Sep 01; 35(5):369-375.

View in: PubMed
Moshfeghi AA, Khurana RN, Moini H, Sherman S, Reed K, Boucher N, Rahimy E. Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice. BMC Ophthalmol. 2024 May 31; 24(1):229.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement